MA50374B1 - Antibody compositions for the treatment of tumors - Google Patents
Antibody compositions for the treatment of tumorsInfo
- Publication number
- MA50374B1 MA50374B1 MA50374A MA50374A MA50374B1 MA 50374 B1 MA50374 B1 MA 50374B1 MA 50374 A MA50374 A MA 50374A MA 50374 A MA50374 A MA 50374A MA 50374 B1 MA50374 B1 MA 50374B1
- Authority
- MA
- Morocco
- Prior art keywords
- binding
- antigen
- bispecific antibodies
- present
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention propose des anticorps bispécifiques qui se lient au cd3 et aux antigènes tumoraux et des procédés d'utilisation de ceux-ci. Selon certains modes de réalisation, les anticorps bispécifiques de l'invention présentent des fonctions effectrices réduites et ont un profil de liaison unique vis-à-vis des récepteurs fcy. Les anticorps bispécifiques sont conçus pour induire efficacement la destruction des cellules tumorales par les lymphocytes t. Selon certains modes de réalisation, la présente invention propose des molécules bispécifiques de liaison à l'antigène comprenant un premier domaine de liaison à l'antigène qui se lie spécifiquement au cd3 humain, une seconde molécule de liaison à l'antigène qui se lie spécifiquement au cd20 humain, et un domaine fc qui lie les récepteurs fcy avec un motif de reliure. Dans certains modes de réalisation, les molécules de liaison d'antigène bispécifiques de la présente invention sont capables d'inhiber la croissance de cellules b ou de tumeurs de mélanome exprimant cd20. Les anticorps bispécifiques de l'invention sont utiles pour le traitement de divers cancers ainsi que d'autres maladies et troubles liés au cd20.The present invention provides bispecific antibodies which bind to cd3 and tumor antigens and methods of use thereof. According to some embodiments, the bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile towards fcy receptors. Bispecific antibodies are designed to efficiently induce destruction of tumor cells by t lymphocytes. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain which binds specifically to human cd3, a second antigen-binding molecule which binds specifically to human cd20, and an fc domain that binds fcy receptors with a binding motif. In certain embodiments, the bispecific antigen binding molecules of the present invention are capable of inhibiting the growth of b cells or melanoma tumors expressing cd20. The bispecific antibodies of the invention are useful for the treatment of various cancers as well as other diseases and disorders related to cd20.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461955663P | 2014-03-19 | 2014-03-19 | |
| US201461981641P | 2014-04-18 | 2014-04-18 | |
| US201462007385P | 2014-06-03 | 2014-06-03 | |
| US201462033460P | 2014-08-05 | 2014-08-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA50374A MA50374A (en) | 2020-01-15 |
| MA50374B1 true MA50374B1 (en) | 2021-06-30 |
Family
ID=58699943
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39751A MA39751B1 (en) | 2014-03-19 | 2015-03-18 | Antibody compositions for the treatment of tumors |
| MA50374A MA50374B1 (en) | 2014-03-19 | 2015-03-18 | Antibody compositions for the treatment of tumors |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39751A MA39751B1 (en) | 2014-03-19 | 2015-03-18 | Antibody compositions for the treatment of tumors |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR099798A1 (en) |
| HR (1) | HRP20210615T1 (en) |
| MA (2) | MA39751B1 (en) |
-
2015
- 2015-03-18 MA MA39751A patent/MA39751B1/en unknown
- 2015-03-18 MA MA50374A patent/MA50374B1/en unknown
- 2015-03-19 AR ARP150100832A patent/AR099798A1/en active IP Right Grant
-
2021
- 2021-04-19 HR HRP20210615TT patent/HRP20210615T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20210615T1 (en) | 2021-05-28 |
| MA39751B1 (en) | 2019-11-29 |
| MA50374A (en) | 2020-01-15 |
| AR099798A1 (en) | 2016-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42542B1 (en) | Molecules Binding to pd-1 and Corresponding Methods of Use | |
| MY205933A (en) | Sirp-alpha binding proteins and methods of use thereof | |
| ZA202206437B (en) | Claudin18.2 binding moieties and uses thereof | |
| EA201691858A1 (en) | ANTIBODY COMPOSITIONS FOR TREATMENT OF TUMORS | |
| MA52773B1 (en) | ANTI-CD3 ANTIBODIES AND THEIR USES | |
| CR20200467A (en) | ANTI-CD25 ANTIBODY AGENTS | |
| PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
| TN2019000294A1 (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| EA202092825A1 (en) | ANTI-SIRPA ANTIBODIES AND METHODS OF THEIR APPLICATION | |
| MX2019013033A (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof. | |
| MX392369B (en) | ANTI-ILT4 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS. | |
| MX346486B (en) | Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies. | |
| EP4467648A3 (en) | Anti-dr5 antibodies and methods of use thereof | |
| EA201792657A1 (en) | Binding LAG-3 MOLECULES AND METHODS OF THEIR APPLICATION | |
| MA42935B1 (en) | Optimized anti-cd3 bispecific antibodies and their uses | |
| MX2015004105A (en) | Human monoclonal anti-pd-l1 antibodies and methods of use. | |
| PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof | |
| MA33402B1 (en) | Formulations and methods of targeting the complementary c3b antibody | |
| EA201400390A1 (en) | ANTIBODIES TO TL1A AND THEIR APPLICATION | |
| EA201791691A1 (en) | SINGLE-DOMAIN ANTIBODIES DIRECTED TO CD1d | |
| EP4253959A3 (en) | Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule | |
| EA202190235A1 (en) | ANTIBODIES TO CD33 AND METHODS OF THEIR APPLICATION | |
| MX2022009915A (en) | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof. | |
| PH12021553121A1 (en) | Novel cthrc1-specific antibody and use thereof | |
| MA50374A (en) | ANTIBODY COMPOSITIONS FOR TREATMENT OF TUMORS |